PART I . GENERAL ORGANIZATION AND BUSINESS Bioxytran, Inc. (we, us, or the Company) is a clinical stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen to tissues. Hypoxia needs to be addressed quickly, otherwise it results in necrosis, which is the death of cells comprising body tissue. Necrosis cannot be reversed. Our lead drug candidate, code named BXT-25, is an oxygen-ca...
Q2 FY2026 — expected 2026-08-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-04-03 | 2024-12-31 | 0001641172-25-002614 | EDGAR | 52K words |
| 2024-03-22 | 2023-12-31 | 0001493152-24-011014 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001493152-23-010104 | EDGAR | — |
| 2022-04-11 | 2021-12-31 | 0001539497-22-000793 | EDGAR | — |
| 2021-04-09 | 2020-12-31 | 0001785982-21-000076 | EDGAR | — |
| 2020-03-18 | 2019-12-31 | 0001213900-20-006766 | EDGAR | — |
| 2019-03-13 | 2018-12-31 | 0001213900-19-004006 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001213900-18-003761 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001213900-17-003123 | EDGAR | — |
| 2016-07-22 | 2015-12-31 | 0001213900-16-015178 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001493152-25-023399 | EDGAR | 24K words |
| 2025-08-11 | 2025-06-30 | 0001493152-25-011797 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001641172-25-010822 | EDGAR | — |
| 2024-10-29 | 2024-09-30 | 0001493152-24-042763 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001493152-24-032356 | EDGAR | — |
| 2024-04-19 | 2024-03-31 | 0001493152-24-015358 | EDGAR | — |
| 2023-11-03 | 2023-09-30 | 0001493152-23-039202 | EDGAR | — |
| 2023-07-31 | 2023-06-30 | 0001493152-23-026050 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001493152-23-016483 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001493152-22-031402 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001493152-22-022572 | EDGAR | — |
| 2022-05-23 | 2022-03-31 | 0001539497-22-001047 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-20 | 0001493152-26-011755 | EDGAR | 1K words |
| 2026-03-13 | 0001493152-26-010045 | EDGAR | — |
| 2026-03-02 | 0001493152-26-008475 | EDGAR | — |
| 2026-02-17 | 0001493152-26-006891 | EDGAR | — |
| 2026-02-11 | 0001493152-26-006081 | EDGAR | — |
| 2026-01-05 | 0001493152-26-000418 | EDGAR | — |
| 2025-12-15 | 0001493152-25-027639 | EDGAR | — |
| 2025-01-22 | 0001493152-25-003136 | EDGAR | — |
| 2025-01-13 | 0001493152-25-001891 | EDGAR | — |
| 2025-01-10 | 0001493152-25-001603 | EDGAR | — |
201 total filings indexed. 169 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001445815 |
| Ticker | BIXT |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report